Hemostemix Inc. (CVE:HEM – Get Free Report) shares reached a new 52-week low during mid-day trading on Friday. The company traded as low as C$0.05 and last traded at C$0.05, with a volume of 99,539 shares changing hands. The stock had previously closed at C$0.06.
Hemostemix Stock Down 9.1%
The company has a debt-to-equity ratio of -61.85, a current ratio of 0.13 and a quick ratio of 0.48. The firm has a market cap of C$10.57 million, a PE ratio of -1.92 and a beta of -0.14. The business has a fifty day moving average price of C$0.06 and a two-hundred day moving average price of C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Recommended Stories
- Five stocks we like better than Hemostemix
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
